[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337239-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337239-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","super-enhancer-mycnos-se-promotes-chemoresistance-in-small-cell-lung-cancer-recruiting-transcription-factors-ctcf-and-klf15","Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer - recruiting transcription factors CTCF and KLF15","","Small cell lung cancer frequently develops resistance to chemotherapy, making molecular mechanisms and actionable targets essential. This study uses RNA-Seq, H3K27Ac, and ATAC-Seq analyses to define super-enhancers and their transcription factors, combining in vitro and in vivo experiments with clinical sample collection for prognostic assessment. MYCNOS is highly expressed and shows chemoresistant effects, mediated by the MYCNOS-SE recruiting CTCF and KLF15 to regulate MYCNOS. MYCNOS modulates chemotherapy sensitivity via the NOTCH pathway and is proposed as a predictive biomarker for patients who may benefit from NOTCH inhibitors, supporting pathway-targeted therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/super-enhancer-mycnos-se-promotes-chemoresistance-in-small-cell-lung-cancer-recruiting-transcription-factors-ctcf-and-klf15/337239/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/super-enhancer-mycnos-se-promotes-chemoresistance-in-small-cell-lung-cancer-recruiting-transcription-factors-ctcf-and-klf15/337239.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this study in small cell lung cancer?","Question",{"text":63,"@type":64},"The study investigates how the super-enhancer MYCNOS-SE and associated transcription factors drive chemoresistance in small cell lung cancer, using molecular profiling and functional validation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does MYCNOS-SE regulate MYCNOS expression?",{"text":68,"@type":64},"MYCNOS-SE recruits transcription factors CTCF and KLF15 to regulate MYCNOS expression, linking enhancer activity to chemoresistant behavior.",{"name":70,"@type":61,"acceptedAnswer":71},"Through which pathway does MYCNOS influence chemotherapy sensitivity?",{"text":72,"@type":64},"MYCNOS modulates chemotherapy sensitivity through the NOTCH pathway, suggesting MYCNOS-linked signaling as a therapeutic and predictive axis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337239,1790269507,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nSuper-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15  \nYuchun Niu1,2,7, Yichun Tang 1,7, Feng Ma2,7, Xuyang Zhou 1, Yi Chen1, Yu Wang 1, Yue Xu3, Lei Sun4, Shaoqiang Liang2, Jianqi Yang5, Kai Wang5, Fan Zhang6 ✉, Shan Su3 ✉ and Linlang Guo1 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Small cell lung cancer (SCLC) is an aggressive form of lung cancer that often becomes resistant to chemotherapy. Understanding the molecular mechanisms of chemoresistance is crucial for identifying effective therapeutic targets. In this study, we used RNA-Seq to identify highly expressed molecules associated with chemoresistance. We also performed H3K27Ac and ATAC-Seq binding analyses to identify super-enhancers (SE) and their corresponding transcription factors. Both in vitro and in vivo experiments were conducted to examine the impact of these molecules and clinical samples were collected to establish their prognostic value. Our ﬁndings revealed elevated expression of MYCNOS, which exhibited chemoresistant properties in both in vitro and in vivo models of SCLC. We identiﬁed MYCNOS-SE as a signiﬁcant SE in SCLC that regulates the distal target gene MYCNOS. This SE recruits transcription factors CTCF and KLF15 to regulate MYCNOS expression. Additionally, MYCNOS, an antisense of MYCN, was found to modulate chemotherapy sensitivity through the NOTCH pathway. This study highlights the signiﬁcance of SE -regulated target genes as markers for chemoresistance in SCLC. Furthermore, it suggests that MYCNOS could serve as a predictor to identify patients who may beneﬁt from NOTCH inhibitors. These ﬁndings provide valuable insights for future studies aimed at developing |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapeutic strategies targeting these identiﬁed pathways. |  |  |\n|  | Oncogene (2025) 44:255–268; [https://doi.org/10.1038/s41388-024-03202-1](https://doi.org/10.1038/s41388-024-03202-1) |  |\n|  |  |  |\n\nINTRODUCTION  \nSmall cell lung cancer (SCLC) is an aggressive and invasive neuroendocrine tumor, constituting approximately 15% of all lung cancer cases [1–4] . Despite decades of research, signiﬁcant breakthroughs in SCLC treatment have remained elusive [5–10] . Initially, patients respond well to chemotherapy, experiencing rapid tumor shrinkage. Nevertheless, repeated cycles of chemotherapy frequently culminate in the development of chemoresistance, ultimately leading to tumor recurrence and metastasis [11–13] . Overcoming chemoresistance and improving survival outcomes pose substantial challenges in managing SCLC [14] .  \nThe regulation of super-enhancers(SE) presents a novel perspective for understanding tumor initiation and progression [15–18] . These key regulatory elements in transcriptional control have emerged as potential targets for therapies [19–21] . Acknowledging the critical role of super-enhancers in driving transcriptional addiction in tumor cells, their implication in drug resistance has garnered increasing recognition. Inhibitors that target SE can suppress oncogene transcription and synergize with chemotherapy agents to overcome drug resistance [18, 22–25] . Therefore,  \ndelving into the mechanisms underlying SE-mediated drug resistance is imperative for advancing clinical management strategies and improving patient outcomes [26–28] .  \nAmpliﬁcation of the MYC family genes has been identiﬁed as a hallmark of distinct subpopulations and drug sensitivities in SCLC patients [29, 30] . MYCN, among these genes, modulates HES1 expression via the NOTCH signaling pathway, thereby contributing to chemoresistance in SCLC [31] . MYCNOS, a natural antisense transcript of MYCN, assumes a pivotal role in enhancing MYCN expression [32–34] . In-depth analyses of H3K27ac ChIP-Seq and ATAC-seq sequencing","cbCailOJG8tKVfuP","https://ap.wps.com/l/cbCailOJG8tKVfuP","pdf",3706645,14,"English","# Introduction\n## Super-enhancers and drug resistance\n## MYC family amplification and MYCNOS\n# Results\n## MYCNOS functions in chemoresistance in vitro and in vivo","[{\"question\":\"What is the main focus of this study in small cell lung cancer?\",\"answer\":\"The study investigates how the super-enhancer MYCNOS-SE and associated transcription factors drive chemoresistance in small cell lung cancer, using molecular profiling and functional validation.\"},{\"question\":\"How does MYCNOS-SE regulate MYCNOS expression?\",\"answer\":\"MYCNOS-SE recruits transcription factors CTCF and KLF15 to regulate MYCNOS expression, linking enhancer activity to chemoresistant behavior.\"},{\"question\":\"Through which pathway does MYCNOS influence chemotherapy sensitivity?\",\"answer\":\"MYCNOS modulates chemotherapy sensitivity through the NOTCH pathway, suggesting MYCNOS-linked signaling as a therapeutic and predictive axis.\"}]","Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer - recruiting transcription factors CTCF and KLF15 | PDF",1790018266,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a1876c73dbf8e9882821f30fb54f9b0.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2feacb965e1811be969422ecfe6c07f1.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcfcb4ed095d10cf85f72a53ee695f46.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efeef864ba78709c1f3d24f85d50faf2.webp",980,1301]